$SOLV WI (-9,68%)

$TMO (-5,69%)

$MMM (-7,03%)

Thermo Fisher acquires Solventum's cleaning unit for 4.1 billion US dollars

Thermo Fisher Scientific Inc. (NYSE: TMO), a global leader in serving science, has announced a definitive agreement to acquire the Purification & Filtration business of Solventum (NYSE: SOLV) for $4.1 billion in cash. This strategic move is expected to expand Thermo Fisher's biomanufacturing capabilities and strengthen its presence in the fast-growing bioprocessing market.

Solventum's Purification & Filtration business, which generated approximately $1 billion in sales in 2024, is known for its purification and filtration technologies. These technologies are essential for the production of biologics, medical devices and various industrial applications. The company employs around 2,500 people in several regions, including the Americas, Europe, Middle East, Africa and Asia-Pacific.

The transaction is expected to close by the end of 2025, subject to customary closing conditions and regulatory approvals. Thermo Fisher forecasts that the acquisition will be initially dilutive to adjusted earnings per share (EPS) by $0.06, excluding financing costs, but accretive to earnings by $0.28 in the first year following the acquisition. The company expects to realize approximately $125 million in adjusted operating income from revenue and cost synergies by the fifth year after closing. According to InvestingPro analysis, Solventum currently trades at an EV/EBITDA multiple of 11.15x, with analysts maintaining price targets between $63 and $82 per share.

A big move for former 3M subsidiary Solventum $SOLV WI (-9,68%)The company has announced that it will sell its purification and filtration business to Thermo Fisher Scientific for a whopping USD 4.1 billion. $TMO (-5,69%) for a whopping USD 4.1 billion. 👍

This deal, which is expected to be completed by the end of 2025, is intended to realign Solventum's business and reduce its debt burden. With net proceeds of approximately USD 3.4 billion, the company plans to mainly reduce its debt.

Bryan Hanson, CEO of Solventum, emphasizes that this sale is part of a comprehensive transformation plan. By focusing on strategic areas, the company aims to create long-term value for shareholders. The transfer of the business to Thermo Fisher, which supplies filters and membranes for various industries, will strengthen Solventum's innovation capabilities and enable the necessary investments in talent and programs.

This move demonstrates the importance for companies to focus on their core competencies while strengthening their financial foundations.

Part 5 of 5
/ Review of the year 2024: In the first 4 parts

of my investment story, I looked at the years 2013 to 2023.

A mixture of highs and lows. While there was a lot of learning at the beginning, the last few years are finally bearing fruit!

Monthly view:

2024 was another very positive year, although December again resulted in a slight loss in the portfolio.

In total, December was -0,8%. This corresponds to price losses of -3.200€.

The MSCI World (benchmark) was -0.9% and the S&P500 -2.5%.

In the following, however, I would like to look primarily at the whole of 2024 and not

just December.

Year as a whole:

Winners & losers:

The winner par excellence is hardly surprising NVIDIA $NVDA (-6,56%) with

almost €20,000 in share price gains! And this despite the fact that I took my entire stake of ~€4,000 off the table in March.

In 2nd place follows Bitcoin
$BTC (+0,24%) with approx. 6,000€ price gains. 3rd-5th place

are shared by TSMC $TSM (-4,94%)
Alphabet $GOOG (-4,08%) and Meta
$META (-7,84%) with gains of ~€5,000 each.

On the loser side it looks very relaxed all in all.

Sartorius $SRT (-3,89%)
Nike $NKE (-9,88%)

and Bechtle $BC8 (+1,31%) have each caused share price losses of ~€1,000. They are followed by LVMH $MC (-4,2%) with share price losses of €500 and Amgen $AMGN (-0,97%) with €200.

All in all, share price losses that are not really worth mentioning.

The performance-neutral movements in 2024 were just under €20,000. This is a significant decline compared to the almost €30,000 from previous years. This was due to some private issues and the upcoming house construction.

My performance for the year as a whole was +28,8% and therefore outperformed my benchmark, the MSCI World, by 25.8%.

In total, my portfolio currently stands at ~347.000€. This

corresponds to an absolute growth of ~95,000€ in the current

year 2023. ~71.000€ of which comes from price gains, ~3.800€ from

dividends / interest and ~20.000€ from additional investments.

Dividend:

• The dividends in December were 17% above the previous year at ~€370
• Amgen is in the lead with over 50€ (gross) dividend every 3 months
• For the year as a whole, my dividends amounted to ~2.900€ and thus almost 25% over 2023

Buys & sells:

- I bought in December for a significantly reduced ~500€

- As always, my savings plans were executed:

- Blue chips: Lockheed Martin $LMT (-0,64%) Republic Services $RSG (-0,95%) Thermo Fisher $TMO (-5,69%) ASML $ASML (-7,2%) Northrop Grumman $NOC (-1,59%) Itochu $8001 (-5,41%) Constellation Software $CSU (-4,52%) Hermes $RMS Salesforce $CRM (-6,16%) MasterCard $MA (-4,05%) Deere $DE (-5,21%)

- Growth: -

- ETFs: MSCI World $XDWD (-4,36%) and the WisdomTree Global Quality Dividend Growth $GGRP (-5,59%)

- Crypto: Bitcoin $BTC (+0,24%) and Ethereum $ETH (-1,11%)

- There were no further sales in December

Target 2024 & outlook 2025:

My goal for 2024 was to reach €300,000 in the portfolio. Due to the

extremely positive market performance in the current year, my portfolio stands at ~€ 350,000 at the end of the year. I was therefore able to significantly exceed my target.

What will happen in 2025? The logical target, of course, would be 400.000€ to be achieved. However, due to the upcoming house construction, part of the assets will be invested in the house construction. If I include the property in my statement of assets, the target of €400,000 would of course not change.

However, as I am more likely to be tracking my liquid assets here, I will probably

probably refrain from doing so.

Therefore, my year-end target for 2025 will probably be closer to the final balance for 2024. So around €350,000 at the end of 2025.

How are things looking for you? Have you already thought about your plans for 2025?

Finally, I wanted to say thank you again for all the positive reactions to my investment story!

https://linktr.ee/mister.ultra

#dividends
#dividende
#rückblick
#depotupdate
#aktie
#stocks
#etfs
#crypto
#personalstrategy

Due to some discussions in my last post about ThermoFisher$TMO (-5,69%) and Itochu $8001 (-5,41%) I have decided to replace ThermoFisher with Itochu. I was looking for diversification and continuous stability (reduction of the US share).

In the end, you can only hope that you don't regret it. European shares in the summer sale.

Today I bought the last tranche of Carl Zeiss Meditec $AFX (-4,84%) today. The reason is of course that I am still convinced of the company, but nobody can say how long it will be before the share comes back to life.

It could probably go down even further, but I have decided not to buy any more from now on as the position is large enough and otherwise my risk management will no longer work.

Overall, I have increased my position size from around 1% to just over 3%, which already represents a clear commitment to a German company, which is known to be particularly volatile.

The same applies to L'Oreal $OR (-1,81%) here, too, I have finished buying with a buy-in of €365 and have reached a position size that is already approaching the 4% portfolio weighting. The shares will probably continue to fall for the time being, which I will simply have to hold on to.

I would now rather concentrate on other opportunities such as Thermo Fisher $TMO (-5,69%) where I have already doubled down this month. Here, however, I can well imagine buying significantly more if prices fall.

It cannot be ruled out that, if the market as a whole weakens, LVMH $MC (-4,2%) and $ASML (-7,2%) a first purchase could take place. With the four stocks already mentioned here (+ $NOVO B (-2,47%) ) mentioned here, I believe that the potential of Western European equities has already been fully exhausted.

It's just a difficult case. Europe is currently more attractive than ever before compared to the hot American market. Either you can seize the opportunity of the decade NOW and bet on a recovery of the European economy, then the champagne corks will pop here in two years' time. Or there will be a complete implosion of the European economy (and then the double-digit losses in the portfolio will be the least of our problems)

Earnings next week 🗓️

$SAP (-2,9%)

$NUE (-10,78%)

$VZ (-0,78%)

$GM (-3,61%)

$MMM (-7,03%)

$RTX (-4,49%)

$GE (-6,76%)

$ENPH (-5,91%)

$TXN (-8,71%)

$VRT (-8,25%)

$BA (-10,31%)

$T (-0,44%)

$KO (-0,07%)

$NEE (+0,26%)

$GEV (-8,19%)

$TMO (-5,69%)

$TSLA (-4,34%)

$LRCX (-11,49%)

$IBM (-3,34%)

$NOW (-4,18%)

$TMUS (+1,59%)

$AAL (-9,83%)

$UPS (-9,71%)

$LUV (-10,15%)

Depot review September 2024 - The first green September in my depot since 2019 📈

September is generally regarded as the worst month on the stock market, with a negative monthly performance more than 50% of the time. This is also consistent with my experience since 2013. In 11 years, it has been negative 6 times and positive 5 times. From 2020 to 2023, the last 4 years were all negative. However, September 2024 is now the first positive September since 2019, which means it is exactly 50/50 for me - 6 positive and 6 negative Septembers since 2013.

The Fed's interest rate turnaround and the stimulus in China have certainly contributed to the positive trend

Monthly view:

In total, September was +1,2%. This corresponds to price gains of ~3.600€.

The MSCI World (benchmark) was +1.0% and the S&P500 +1.3%

Winners & losers:

A look at the winners and losers is particularly exciting this month.

On the winning side at the very top are my China ETF with € +1,300 and is thus back in the green for the first time in a long time. The following winners are also a colorful mix with Meta, Bitcoin, Home Depot and Sea. Really a very broad mix with no clear tendency towards regions, sectors or the like

On the loser side in my portfolio in September were mainly pharmaceutical stocks. Novo Nordisk, Amgen and Johnson & Johnson. Even worse, with price losses of ~€700 each, were only Palo Alto Networks and ASML.

The performance-neutral movements in September were just under €4,500. The premium refund from my private health insurance also played a large part in this. In September, I received over €2,000 back for the year 2023, which was of course invested directly to compensate for any higher pension contributions.

Current year:

My performance in the current year is +20,4% and thus above my benchmark, the MSCI World with 17.2%.

In total, my portfolio currently stands at ~321.000€. This corresponds to an absolute growth of ~€69,000 in the current year 2023. ~49.000€ of this comes from price increases, ~2.800€ from dividends / interest and ~17.000€ from additional investments.

Dividend:

• Dividends in September were 23% above the previous year at ~€360
• Amgen is in the lead with a (gross) dividend of €50 every 3 months. But Johnson & Johnson with €45 is also a delight
• In the current year, the dividends after 9 months are +25% over the first 9 months of 2023 at ~2.210€

Buys & sells:

• I bought in September for approx. 3,500€. 2,100 of this came from the premium refund from my private health insurance and went into the WisdomTree Global Quality Dividend Growth
• As always, my savings plans were executed:
• Blue ChipsLockheed Martin $LMT (-0,64%) Republic Services $RSG (-0,95%) Thermo Fisher $TMO (-5,69%) ASML $ASML (-7,2%) MasterCard $MA (-4,05%) Deere $DE (-5,21%) Northrop Grumman $NOC (-1,59%) Itochu $8001 (-5,41%) Salesforce $CRM (-6,16%) Hermes $RMS (-3,46%) Constellation Software $CSU (-4,52%)
• 
  Growth: -
• ETFsMSCI World $XDWD (-4,36%) Nikkei 225 $XDJP (-4,67%) and the WisdomTree Global Quality Dividend Growth $GGRP (-5,59%)
• 
  Crypto: Bitcoin $BTC (+0,24%) and Ethereum $ETH (-1,11%)
• 
  Sales there were none in September

Target 2024:

My goal for this year is to reach €300,000 in my portfolio. Due to the extremely positive market development in the current year, my portfolio currently stands at ~€321,000.

At the beginning of September, my portfolio was still quite a bit lower at €304,000 due to the weak start to the month. At this point, it was therefore quite a way off the previous high of €320,000 in June.

I have now reached a new high of €321,000 and am optimistic that I can still beat my year-end target of €300,000.

#dividends

#dividende

#rückblick

#depotupdate

#aktie

#stocks

#etfs

#crypto

#personalstrategy

Thermo Fisher Scientific is a leader in life science technology, offering a broad range of products and services for research, diagnostics and manufacturing in healthcare, life sciences and other industries. The company has a strong market position and is experiencing continuous growth.

These include instruments, consumables, reagents, software and services for research, diagnostics and production in healthcare, life sciences and other industries. The company offers solutions for the analysis of DNA, RNA, proteins, cells, drugs, etc.

Thermo Fisher is known for its high-quality products and its commitment to advancing scientific discovery and progress. In 2023, research and development spending amounted to $1.5 billion, approximately 3.2% of annual sales.

Virtually every laboratory works with Thermo Fisher products. Its customer base includes over 400,000 laboratories, ranging from small research institutions to large pharmaceutical companies.

Thermo Fisher Scientific brands include Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific and Unity Lab Services.

Market capitalization: ~€200 billion

Sales: $43 billion /2023

P/E RATIO: 36

Dividend yield: 0.252% Quarterly dividend growth: 10% over 10 years

Sales by region:

53% USA

25% Europe

18% Asia-Pacific

Employees: <100,000

Return 20 years: 1,837.83%

Future opportunities:

- Continuous sales and growth

- Healthcare industry trend: ThermoFisher is well positioned and will benefit from new technologies [e.g. AI-supported data analysis]

- Innovation leader: Investments in research and development strengthen and maintain ThermoFisher's market position

- Global demand, highly diversified product range

What do you think about Thermo Fisher?

I have a long-term holding in the portfolio myself. TF is the market leader and cannot be overtaken or replaced so quickly. When it comes to healthcare research, TF is directly and indirectly involved. People are becoming more numerous, older and sicker. This means that growth will not slow down for the time being.

https://ir.thermofisher.com/investors/overview/default.aspx

#thermofisher
$TMO (-5,69%)
#gesundheitsbranche